The cytotoxic and stress responses of human trabecular meshwork cells treated with triamcinolone acetonide

Molecular Vision

Volumn 14, Issue , 2008, Pages 105-113

  Wang, Dan Yi ^a,b   Fan, Bao Jian ^a,b   Yam, Gary Y H ^a   Lam, Dennis S C ^a   Pang, Chi Pui ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BENZYL ALCOHOL; CASPASE 3; DRUG VEHICLE; MYC PROTEIN; PROTEIN C FOS; PROTEIN C JUN; PROTEIN P53; TRIAMCINOLONE ACETONIDE;

ANALYSIS OF VARIANCE; APOPTOSIS; ARTICLE; CELL ASSAY; CELL CULTURE; CELL PROLIFERATION; CELL STRESS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAOCULAR HYPERTENSION; NICK END LABELING; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; STUDENT T TEST; TRABECULAR MESHWORK;

APOPTOSIS; CASPASE 3; CELL COUNT; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; GLUCOCORTICOIDS; HUMANS; PROTO-ONCOGENE PROTEINS; TIME FACTORS; TRABECULAR MESHWORK; TRIAMCINOLONE ACETONIDE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 38649107678     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Antcliff RJ, Spalton DJ, Stanford MR, Graham EM, Ffytche TJ, Marshall J. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 2001, 108:765-72.
2. Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Experiment Ophthalmol 2001, 29:2-6.
3. Jonas JB, Hayler JK, Sofker A, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2001; 131:468-71.
4. Lam DS, Chan CK, Tang EW, Li KK, Fan DS, Chan WM. Intravitreal triamcinolone for diabetic macular oedema in Chinese patients: six-month prospective longitudinal pilot study. Clin Experiment Ophthalmol 2004; 32:569-72.
5. Jonas JB, Hayler JK, Panda-Jonas S. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferaive vitreoretinopathy. Br J Ophthalmol 2000; 84:1064-7.
6. Danis RP, Ciulla TA, Pratt LM, Anliker W. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000; 20:244-50.
7. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitral injection of triamcinolone acetonide. Br J Ophthalmol 2001; 87:24-7.
8. Kaushik S, Gupta V, Gupta A, Dogra MR, Singh R. Intractable glaucoma following intravitreal triamcinolone in central retinal vein occlusion. Am J Ophthalmol 2004; 137:758-60.
9. Benz MS, Albini TA, Holz ER, Lakhanpal RR, Westfall AC, Iyer MN, Carvounis PE. Short-term course of intraocular pressure after intravitreal injection of triamcinolone acetonide. Ophthalmology 2006; 113:1174-8.
10. Dierks D, Lei B, Zhang K, Hainsworth DP. Electroretinographic effects of an intravitreal injection of triamcinolone in rabbit retina. Arch Ophthalmol 2005; 123:1563-9.
11. Ruiz-Moreno JM, Montero JA, Bayon A, Rueda J, Vidal M. Retinal toxicity of intravitreal triamcinolone acetonide at high doses in the rabbit. Exp Eye Res 2007; 84:342-8.
12. Albini TA, Abd-El-Barr MM, Carvounis PE, Iyer MN, Lakbanpal RR, Pennesii ME, Chevez-Garrios P, Wu SM, Holz ER. Long-term retinal toxicity of intravitreal commercially available triamcinolone acetonide (Kenalog) in rabbit eyes. Invest Ophthalmol Vis Sci 2007; 48:390-5.
13. Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology 2005; 112:593-8.
14. Lee EW, Hariprasad SM, Mieler WF, Newman TL, Apte RS. Short-term intraocular pressure trends after intravitreal triamcinolone acetoliide injection. Am J Ophthalmol 2007; 143:365-7.
15. Beer PM, Bakri SJ, Singh RJ, Liu W, Peters GB 3rd, Miller M. Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003; 110:681-6.
16. Tan JC, Peters DM, Kaufman PL. Recent developments in understanding the pathophysiology of elevated intraocular pressure. Curr Opin Ophthalmol 2006; 17:168-74.
17. Jones R III, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol 2006; 17:163-7.
18. Yeung CK, Chan KP, Chiang SW, Pang CP, Lam DS. The toxic and stress responses of cultured human retinal pigment epithelium (ARPE19) and human glial cells (SVG) in the presence of triamcinolone. Invest Ophthalmol Vis Sci 2003; 44:5293-300.
19. Tong JP, Lam DSC, Chan WM, Choy KW, Chan KP, Pang CP. Effects of triamcinolone on the expression of VEGF and PEDF in human retinal pigment epithelium (ARPE19) and human umbilical vein endothelial (HUVE) cells. Mol Vis 2006; 12:1490-5.
20. Chu KO, Ho TC, Chiang WY, Wang CC, Lam DS, Pang CP. Measuring triamcinolone acetonide in aqueous humor by gas chromatography-electron-capture negative-ion mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 847:199-204.
21. Mason JO, Somaiya MD, Singh RJ. Intravitreal concentration and clearance of triamcinolone acetoliide in nonvitrectornized human eyes. Retina 2004; 24:900-4.
22. Kubota T, Okabe H, Hisatomi T, Yamakiri K, Sakamoto T, Tawara A. Ultrastructure of the trabecular meshwork in secondary glaucoma eyes after intravitreal triamcinolone acetonide. J Glaucoma 2006; 15:117-9.
23. Polansky JR, Fauss DJ, Chen P, Chen H, Lutjen-Drecoll E, Johnson D, Kuitz RM, Ma ZD, Bloom E, Nguyen TD. Cellular pharmacology and molecular biology of the trabecular meshwork inducible glucocorticoid response gene product. Ophthalmologica 1997; 211:126-39.
24. National Toxicology Program. NTP toxicology and carcinogenesis studies of Benzyl Alcoho (CAS No. 100-51-6) in F344/N rats and B6C3F1 mice (Gavage studies). Natl Toxicol Program Tech Rep Ser 1989; 343:1-158.
25. Alvarado J, Murphy C, Juster R. Trabecular meshwork cellularity in primary open-angle glaucoma and nonglancomatous normas. Ophthalmology 1984; 91:564-79.
26. Grierson I, Howes RC. Age-related depletion of the celll population in the human trabecular meshwork. Eye 1987; 1:204-10.
27. Wilson SE. Stimulus-specific and cell type-specific cascades: emerging principles relating to control of apoptosis in the eye. Exp Eye Res 1999; 69:255-66.
28. Kong AN, Yu R, Lei W, Mandlekar S, Tan TH, Ucker DS. Differential activation of MAPK and ICE/Ced-3 protease in chemical-induced apoptosis. The role of oxidative stress in the regulation of mitogen-activated protein kinases (MAPKs) leading to gene expression and survival or activation of caspases leading to apoptosis. Restor Neurol Neurosci 1998; 12:63-70.
29. Quigley HA, Yang Z, Qian J, Pease ME, Yang Y, Zack D. Changes in Gene Expression in Experimental Glaucoma and Optic Nerve Transection. ARVO Annual Meeting: 2007 May 6-10; Fort Lauderdale (FL).
30. Gartel AL, Shchors K. Mechanisms of c-myc-mediated transcriptional repression of growth arrest genes. Exp Cell Res 2003; 283:17-21.
31. Oster SK, Ho CS, Soucie EL, Penn LZ. The myc oncogene: MarvelouslY Complex. Adv Cancer Res 2002; 84:81-154.
32. Huerta S, Goulet EJ, Huerta-Yepez S, Livingston EH. Screening and detection of apoptosis. J Surg Res 2007; 139:143-56.
33. Grasl-Kraupp B, Ruttkay-Nedecky B, Koudelka H, Bukowska K, Bursch W, Schulte-Hermann R. In situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: a cautionary note. Hepatology 1995; 21:1465-8.